Boehringer Ingelheim and IBM Collaborate to Advance Generative AI and Foundation Models for Therapeutic Antibody Development

[ad_1] Ingelheim, Germany and Armonk N.Y., November 28, 2023 – Today, Boehringer Ingelheim and IBM (NYSE:IBM) announced an agreement that will enable Boehringer to use IBM’s foundation model technologies to discover…

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

[ad_1] Article content INGELHEIM, Germany & BASEL, Switzerland — Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an…

Boehringer launches 81% discounted biosimilar of AbbVie’s Humira

[ad_1] The logo of German pharmaceutical company Boehringer Ingelheim is seen at its building in Shanghai, China February 1, 2019. REUTERS/Stringer/File Photo Acquire Licensing Rights Oct 2 (Reuters) – Germany’s…

Boehringer Ingelheim invests €350m in new biotech R&D facility

[ad_1] The new €350 million biotechnology R&D centre is Boehringer Ingelheim’s largest single investment in Germany to date. Credit: nitpicker / Shutterstock.com Boehringer Ingelheim has inaugurated its new Biologicals Development…